MARKET

PRTA

PRTA

Prothena
NASDAQ
7.48
+0.05
+0.67%
Opening 12:41 05/12 EDT
OPEN
7.57
PREV CLOSE
7.43
HIGH
8.05
LOW
7.17
VOLUME
587.03K
TURNOVER
0
52 WEEK HIGH
25.42
52 WEEK LOW
6.92
MARKET CAP
402.63M
P/E (TTM)
-3.6015
1D
5D
1M
3M
1Y
5Y
1D
Cisco, Walmart Set To Report Results As Markets Watch Out For Core CPI
Seeking Alpha · 2d ago
Catalyst Watch: China trade talks, Walmart earnings, and Take-Two on the GTA hot seat
Seeking Alpha · 2d ago
Prothena Price Target Cut to $30.00/Share From $48.00 by HC Wainwright & Co.
Dow Jones · 2d ago
Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025
NASDAQ · 2d ago
Prothena Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 2d ago
HC Wainwright & Co. Maintains Buy on Prothena Corp, Lowers Price Target to $30
Benzinga · 2d ago
Prothena Is Maintained at Market Outperform by JMP Securities
Dow Jones · 3d ago
Prothena Price Target Cut to $78.00/Share From $80.00 by JMP Securities
Dow Jones · 3d ago
More
About PRTA
More
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Recently
Symbol
Price
%Change

Webull offers Prothena Corporation PLC stock information, including NASDAQ: PRTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRTA stock methods without spending real money on the virtual paper trading platform.